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The use of 18F-ﬂuorodeoxyglucose positron emission tomography (FDG-PET) for response assessment in lymphoma is now
widespread. Prognostic information obtained from PET performed after two to three cycles of chemotherapy may guide
more individualized, risk-adapted therapeutic strategies. Progress in the risk stratiﬁcation of Hodgkin’s lymphoma through
midtreatment PET is reviewed, with a focus on management implications in newly diagnosed and relapsed disease. How to tailor
treatment on the basis of the interim PET result is not yet deﬁned but is the subject of ongoing trials.
1.Introduction
Strategies that minimize toxicity, without compromising
disease control, are a leading area of research in Hodgkin’s
lymphoma (HL). Because the majority of HL patients
are cured, investigations can now focus upon reducing
treatment toxicities[1, 2]. However, a clearsubset ofpatients
has progressive or relapsed disease and may beneﬁt from a
preemptive, tailored approach. More accurate prognostica-
tion could identify such poor-risk patients, while sparing
good-risk patients from the toxicities of overly intensive
therapy.
In the assessment of treatment response, there are lim-
itations in the prognostic information provided by com-
puted tomography (CT). Residual masses are frequent after
lymphoma therapy, particularly with initial bulky disease
[3, 4]. Yet, it is recognized that their presence and size
correlate poorly with outcome [3–5]. This underlies the
response category of “complete remission unconﬁrmed” in
the 1999 International Working Group criteria [6]. 18F-ﬂuo-
rodeoxyglucose positron emission tomography (FDG-PET)
enhances the ability to distinguish between viable tumor
and ﬁbrosis or necrosis in residual masses [7, 8]. Given
this and the increasingly widespread use of PET in response
assessment, PET hasbeen integrated into therecently revised
response criteria for lymphoma [9, 10]. When performed
midtreatment, PETalsoprovidesvaluableinformationabout
the quality of the treatment response and ultimate prognosis
in patients with aggressive lymphomas including HL. The
prognostication of HL on the basis of early metabolic
imaging with PET is reviewed and treatment implications
considered.
2. PretreatmentPrognostic Indices in HL
The International Prognostic Score (IPS) remains the
most commonly used scoring system for newly diagnosed,
advanced HL [11]. This consists of seven pretreatment vari-
ables that independently predict inferior outcome: albumin
<4g/dL, hemoglobin <10.5g/dL, male sex, age ≥45 years,
stage IV disease, white blood cell count ≥15,000/mm3,a n d
lymphocytopenia (lymphocyte count <600/mm3 or <8% of
the white blood cell count). Each adverse factor is similarly
prognostic, reducing the 5-year freedom from progression
(FFP) rate by approximately 8%, with the estimated 5-year
FFP ranging from 84% with no risk factors to 42% with ≥5
factors in the original paper. The IPS has been utilized in
the design and analysis of clinical studies and may guide the
choice of chemotherapy in individual patients.2 Advances in Hematology
For early stage disease, cooperative groups have used
other baseline criteria for risk stratiﬁcation and treatment
selection [1, 12–14]. Shared factors have included the degree
o fe l e v a t i o ni ne r y t h r o c y t es e d i m e n t a t i o nr a t e ,t h en u m b e r
of involved regions, and the presence of bulky disease. Stage
IIB is often regarded as advanced disease.
Such pretreatment indices are useful in characterizing
groups of patients. However, they are less useful in the prog-
nostication of an individual patient. Furthermore, these are
static rather than dynamic parameters and do not provide
information about the quality of the treatment response. In
contrast, metabolic imaging performed early in the course
of therapy provides useful, individualized information about
the quality of response and about prognosis.
3.PosttreatmentPETinHL
For PET scans performed after the end of chemotherapy
or chemoradiation for HL, the negative predictive value
(NPV, i.e., negative PET scan and no treatment failure) has
been consistently high—approximately 90% [15–20]. This
is despite some of the studies being restricted to patients
with residual masses [15, 18, 20]. In contrast, the reported
positive predictive value (PPV, i.e., positive PET scan and
treatment failure) is weaker and varies widely, ranging from
26% to 74% in representative series [17–20]. As such, a
positive posttreatment PET scan should be interpreted with
particular caution, especially within two to three months of
RT [9].
It must be kept in mind that, even in a reliably FDG avid
tumor, a negative PET does not necessarily signify complete
eradication of disease [21]. The limit of resolution of current
PET systems for detecting tumor generally ranges between
0.5 and 1cm [22, 23], which translates into an estimated 108
to 109 cells. Therefore, millions of viable tumor cells could
persist despite the achievement of a negative PET scan [21].
Thishassubstantialimplicationsforthestudyofde-escalated
therapy in patients with a negative interim PET.
4.MidtreatmentPET andPrognosis in
Newly Diagnosed HL
Earlier identiﬁcation of chemoresistant disease, prior to
treatment completion, would facilitate an individualized,
risk-adapted strategy. Midtreatment (interim) metabolic
imaging via FDG-PET has strong potential in this regard. In
HL and aggressive B-cell non-Hodgkin’s lymphoma (NHL),
it has been repeatedly recognized that PET performed
after only 2 or 3 cycles of chemotherapy provides valuable
prognosticinformation. Early achievementofanegative PET
(absence of abnormal FDG uptake concerning for tumor) is
prognostically favorable, whereas persistent abnormal FDG
uptake on early PET, even in the context of a CT response,
raises concern for treatment failure [24]. PET performed
after only one cycle also appears to have prognostic signiﬁ-
cance [25, 26].
Why can interim PET provide more valuable prognostic
information than one at the end of therapy? An early PET
result may oﬀer a window into the chemosensitivity of
the tumor. As previously reviewed [21], cancers are usually
not diagnosed until they reach a size of 1010 to 1011 cells.
Chemotherapy kills tumor by ﬁrst-order kinetics; that is, a
given dose kills the same fraction, not the same number,
of cells regardless of tumor size [27]. Thus, in the idealized
setting, each cycle of chemotherapy must kill approximately
1.5 to 2 logs of tumor for a lymphoma to be cured after 6
cycles. Accordingly, most of the tumor cell kill should occur
early—with the ﬁrst 2 cycles [21]. A negative cycle 2 PET
implies that the rate of tumor cell kill is suﬃcient to produce
cure by the end of treatment, whereas a negative scan late in
treatment does not distinguish between 4 logs of kill (PET
remission) and the 10 or 11 logs of kill necessary for cure
[21].
As in NHL, the literature on the prognostic signiﬁcance
of interim PET in newly diagnosed HL represents a mixture
of prospective and retrospective studies (Table 1), utilizing
variable scanning techniques and criteria for PET interpre-
tation [25, 28–38]. In a meta-analysis of interim PET in 360
patients with newly diagnosed advanced HL, the sensitivity
of interim PET was 0.81 (95% conﬁdence interval, 0.72 to
0.89) and the speciﬁcity was 0.97 (95% conﬁdence interval,
0.94 to 0.99); corresponding sensitivity and speciﬁcity for
diﬀuse large B-cell lymphoma were 0.78 and 0.87 [24].
FDG-PET performed after 2 cycles of ABVD (doxoru-
bicin, bleomycin, vinblastine, dacarbazine) complements
and ispotentially superior tothe IPS [39]. Inthe widely cited
s t u d yb yG a l l a m i n ie ta l .[ 31], 260 patients with poorer-risk
HL were prospectively evaluated with cycle 2 PET, without
change of therapy. The estimated 2-year progression-free
survival was 95% in those with a negative interim PET, but
only 13% in those with a positive interim PET. On univariate
analysis, the cycle 2 PET result and the IPS were among
the variables that were statistically signiﬁcantly associated
with treatment outcome. Notably, however, on multivariate
analysis, onlycycle2PETandthepresenceofstageIVdisease
were independently associated with outcome.
The majority of data on the prognostic signiﬁcance of
interim PET in HL is in patients with more advanced disease
[31, 32, 36, 38]. Of these, the majority of patients had an
IPS of <4[ 24]. The prognostic value of interim PET in
early stage, favorable disease is not well established. One
would expect, given the greater pretest probability of early
stage patients being cured, that the high NPV observed in
advanced HL would also hold for early stage HL provided
that treatment is not de-escalated. In contrast to the high
NPV of interim PET, the observed PPV has been variable
(Table 1). Furthermore, relatively few patients with positive
interim PET have been studied (50 in the largest series)
[31]. This is an important consideration when treatment
intensiﬁcation is contemplated on the basis of a positive
PET, given the risk of greater toxicity with more intensive
treatment.
An u m b e ro fo t h e rf a c t o r sm a ya c c o u n tf o rt h eo b s e r v e d
variability in the PPV of interim PET. As in NHL, the
variability is likely due in part to methodological diﬀerences
among the studies. Variable (but mostly qualitative) criteria
have been used in deﬁning a positive scan, with borderlineAdvances in Hematology 3
Table 1: PET during ﬁrst-line chemotherapy for Hodgkin’s lymphoma.
Study Prospective No. Stage Chemo, ±RT
Cycles
before
PET
No. PET+
(%) PPV NPV EFS, PET+ EFS, PET– Median
follow-up
Friedberg et al.
2004 [28] yes 22 I–IV; 28%
III-IV
Mostly
ABVD 3 5 (23%) 80% 94% — — 24mo
Hutchings et al.
2005 [29] no 85 I–IV; 33%
III-IV
Mostly
ABVD 2-3 13 (15%)
a 61.5% 94% 46% (2y) 97% (2y) 40mo
39% (5y) 92% (5y)
Gallamini et al.
2006 [34] yes 108
IIA with RF,
IIB-IV; 46%
III-IV
Mostly
ABVD 2 20 (19%) 90% 97% 6% (2y) 96% (2y) 20mo
(mean)
Hutchings et al.
2006 [30] yes 77 I-IV; 36%
III-IV
Mostly
ABVD 2 16 (21%)
a 69% 95% 0% (2y) 96% (2y) 23mo
64 4 13 (20%) 85% 96% 19% (2y) 96% (2y) 23mo
Zinzani et al.
2006 [32] yes 40 IIB-IV; 48%
III-IV ABVD 2 8 (20%)
b 100% 100% — — 18mo
40 4 7 (18%)
b 100% 100% — — 18mo
Kostakoglu et al.
2006 [25] no 23 II–IV; 35%
III-IV ABVD 1 6 (26%) 83% 100% 17% (2y) 100%(2y) 20mo
Querellou et al.
2006 [33] no 44 IIA-IV; 63%
III-IV
Mostly
ABVD 3-4 —c — 95%c — 95% (1y) 18mo
Gallamini et al.
2007 [31] yes 260d
IIA with RF,
IIB-IV; 47%
III–IV
Mostly
ABVD 2 50 (19%)
a 86% 95% 13% (2y) 95% (2y) 26mo
Sher et al. 2009
[35] no 46 Mostly I-II ABVD-
based
e — 20 (43%) 15% 96% 85% (2y) 96% (2y)
f —
Markova et al.
2009 [36] no 50
IIB with RF,
III–IV; 78%
III–IV
BEACOPP 4 14 (28%) 14%g 97%h 86% (2 y)
g 97% (2y) 25mo
Furth et al. 2009
[37] yes 40 I–IV; 48%
III-IV OEPA
i 2 14 (35%) 14% 100% 86% (4y) 100%(4y) 46mo
Avigdor et al.
2009 [38] yes 45 IIB-IV; 93%
III–IV
BEACOPPesc
× 2, then
ABVD
j
2 13 (29%) 45% 87% 53% (4y) 87% (4y) 48mo
ABVD: doxorubicin, bleomycin, vinblastine, dacarbazine; BEACOPP: bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine,
prednisone; EFS: event-free survival; esc: escalated; MRU: minimal residual uptake; NPV: negative predictive value; OEPA: vincristine,etoposide, prednisone,
doxorubicin;PPV:positivepredictivevalue;RF:riskfactor(s);RT: radiationtherapy.Deﬁnitionofaneventvariablyincludesrelapseorprogression,incomplete
remission, disease-related death, and/or any death; starting points for EFS estimates vary. Table modiﬁed from Kasamon et al. [21].
aMRU cases were analyzed with PET− cases.
bMRU cases (4 after cycle2 PET, 3 after cycle4 PET) were analyzed separately; 1 relapsed.
c4/24 patients were PET+, 1 being newly diagnosed; 18/20 PET− patients were newly diagnosed.
dIncludes previously reported patients [30, 34].
eAll received radiation.
fFor interim and post-chemotherapy PET− disease; 1/26 was interim PET−, post-chemotherapy PET+.
g7/14 received RT, which was restricted to >2.5cm, PET+ masseson post-chemotherapyimaging.
hIncludes 1 non-relapse death.
iPediatric study;98% received RT.
jResponse-adapted study; with or without additional therapy.
cases of “minimal residual uptake” [30] posing particular
challenges as later discussed. There are also diﬀerences in
image acquisition protocols and technique; for example,
earlier studies used PET alone, in contrast to combination
PET/CT.
In addition, false positive signals from inﬂammation are
a leading consideration [40], as are other causes of false
positive signals including infection, supraclavicular brown
fat, granulocyte colony stimulating factors in bone marrow
disease [41], bony lesions, and in the case of posttherapy
scans, thymic hyperplasia which can mimic mediastinal
disease. False positives due to inﬂammation are possible in
any type of tumor, but are a particular consideration in HL
givenitsuniquehistopathology.IncontrasttoNHL,lessthan
1% of the tumor mass in HL is comprised of the malignant
Hodgkin and Reed-Sternbergcells; rather, most ofthe tumor4 Advances in Hematology
is comprised of nonmalignant cells, with the nature of that
cellularityhaving prognostic signiﬁcance [42, 43].This raises
the question, what are the histologic underpinnings of a
positive PET signal in HL?
Moreover, the prognostic utility of any criterion can
be a moving target, depending on the eﬀectiveness of the
underlying regimen. Thus, the prognostic and predictive
value of interim PET could vary depending on whether
one receives ABVD versus BEACOPP (bleomycin, etoposide,
doxorubicin, cyclophosphamide, vincristine, procarbazine,
prednisone) [39], or chemotherapy alone versus combined
modality therapy. The PPV of interim PET may indeed be
lower after BEACOPP [36, 39].
5.Risk-AdaptedStrategiesin
Newly Diagnosed HL
Risk-adaptedapproachesinlymphomautilizinginterimPET
a r ef e a s i b l ea n dh o l dp r o m i s e[ 13, 44–46]. Multicenter trials
are in progress in patients with newly diagnosed, limited
stage [47–49] and advanced stage HL [50–54], evaluating
risk-adapted strategies based on the results of interim PET
(Table 2). Most of these trials focus upon adult HL, although
interim PET is also being investigated in pediatric HL [55].
5.1. Risk-Adapted Strategies in Limited Stage HL. In limited
stage HL, a central question is whether therapy can be safely
de-escalated or abbreviated, including through the omission
of RT, in patients achieving a negative interim PET result
during initial chemotherapy [47–49].
The prognostic information provided by early metabolic
imaging may inform decisions about RT in limited stage HL.
The role of using interim PET for this purpose cannot be
considered standard but is in the process of being deﬁned.
Limited stage HL is traditionally treated with combined
modality therapy. However, the eﬀectiveness of RT for local
control of HL must be balanced by the risks of late toxicities,
including second malignancies and cardiovascular disease
[56]. Such toxicities are leading causes of morbidity and
mortality in patients who are cured of their lymphoma.
Concerns about the late eﬀects of RT have led to concerted
eﬀortstodeﬁnetheminimum amount ofradiation necessary
to maintain cure rates. These include reduction in RT dose
(e.g., from 30 to 20 Gray [14]) and the move from extended-
ﬁeldtoinvolved-ﬁeld[2]to,mostrecently,involved-nodeRT
[57].
The appropriateness of chemotherapy alone for limited
stage HL is a matter of debate. Chemotherapy alone has,
however, emerged as a viable alternative to chemoradiation,
at least in patients with nonbulky disease. A statistically
signiﬁcant overall survival diﬀerence has not been conclu-
sively shown with the omission of RT in nonbulky, stage
Io rI IH L[ 1, 58, 59]. A randomized study that found a
diﬀerence in favor of RT had methodological limitations
[60]. However, the risk of relapse has been higher with the
omission of RT [1, 58]. In the HD6 trial of limited stage,
nonbulky HL, the 5-year freedom-from progression after
ABVD alone was 87%, versus 93% in the group that received
RT (P = .06) [1]. As such, a minority of patients are aﬀected
by the omission of radiation. Of note, the rapidity of the
chemotherapeutic response may identify this subset, as the
5-year FFP was signiﬁcantly better in those who achieved
CR or unconﬁrmed CR by anatomic criteria after 2 cycles
of ABVD (95% at 5 years, versus 81% in those who did not;
P = .007) [1]. It is possible that early prognostication via
interim PET may help to diﬀerentiate these subsets, thereby
identifying who least stands to beneﬁt from the addition of
RT. The impact of this approach remains to be determined.
In limited-stage HL, three large, multicenter, randomized
trials are basing the radiation decision upon the results
of PET performed after 2 or 3 cycles of ABVD (Table 2)
[47–49]. All three trials investigate the omission of RT in
patients who achieve a negative PET after 2 or 3 cycles of
ABVD.
In terms of the number of chemotherapy cycles, caution
is advised when considering de-escalating therapy on the
basis of a negative interim PET result. The generally favor-
able outcomes of interim PET negative patients occurred
following unabbreviated therapy. In the H10 trial involving
PET after 2 ABVD cycles for stage I-II HL, additional
chemotherapy is given to the PET negative patients who do
not receive RT (Table 2)[ 49]. Notably, this trial includes
patients with either favorable or unfavorable (including
bulky) disease. In contrast, in the HD16 trial which is
restricted to early favorable disease (stage I-II without risk
factors), patients with a negative PET after 2 cycles of
ABVD receive no further therapy in the experimental arm
[48]. Similarly, in the RAPID trial which is restricted to
nonbulky, stage IA or IIA disease, interim PET negative
patientswho are randomized tothe no-radiation armreceive
no further chemotherapy [47]. Particularly if RT is omitted,
one risks undertreatment if an adequate course of systemic
chemotherapy is not delivered, as a negative PET scan may
not indicate absence of disease. The results of these trials
are awaited. The early cessation of chemotherapy because
of a negative interim PET cannot be supported outside of a
clinical trial.
In the risk-adapted management of HL, an additional
consideration is that resistance to radiation and resistance to
chemotherapy often coexist. This is exempliﬁed by the lower
likelihood of radiation eradicating the tumor if relapse or
progression occursshortly(lessthanayear)afterchemother-
apy [61]. In addition, tumors that respond suboptimally
to chemotherapy commonly relapse or progress within the
radiation ﬁeld. For example, in a retrospective study of 81
HLpatientstreated withStanfordVchemotherapy,4outof6
patients with a positive PET before pre-planned RT relapsed;
3oftheserelapsesoccurredwithintheradiationﬁeldandone
at the margin [62]. RT may also increase the risk of toxicity
from subsequent potentially curative therapies such as blood
or marrow transplantation (BMT). As such, in patients with
positive interim or postchemotherapy PET scans, RT should
not necessarily be considered the appropriate next step.
AlthoughatruepositivePETmayidentifyasubsetwhostand
to beneﬁt from RT, a true positive PET might also identify a
subset who stand not to beneﬁt from RT.Advances in Hematology 5
Table 2: Current risk-adapted studies using interim PET in Hodgkin’s lymphoma.
Study Group Projected
accrual Timing of PET Treatment
Limited disease:
RAPID trial [47] UK NCRI 1600 After ABVD×3P E T −, randomize to RT versus no further therapy
PET+, further ABVD + RT
HD16 [48] GHSG 1100 After ABVD×2 Standard arm: RT regardless of PET
Experimental: PET−, no further therapy
Experimental: PET+, RT
H10 [49] EORTC, GELA, IIL 1600 After ABVD×2 Standard arm: complete ABVD + RT regardless of PET
Experimental: PET−,c o m p l e t eA B V D( n oR T )
Experimental: PET+, BEACOPPesc then RT
Advanced disease:
HD18 [50] GHSG 1500 After BEACOPPesc×2P E T −, randomize to 2 versus 6 more cycles (no RT)
PET+, randomize to BEACOPPesc with versus without rituximab
a
HD0607 [53] GITIL 450 After ABVD×2P E T −, complete ABVD; if still PET–, randomize to RT versus no RT
PET+, randomize to BEACOPPesc with versus without rituximab
b
RATHL [51] UK NCRI 1200 After ABVD×2P E T −,r a n d o m i z et oA B V Dv e r s u sA V D( n oR T )
PET+, BEACOPP-14 or BEACOPPesc
HD0801 [52] IIL 300 After ABVD×2P E T −, complete ABVD; if still PET–, randomize to RT versus no RT
PET+, high-dose therapy with autologous BMT
S0816 [54] SWOG intergroup 230 After ABVD×2P E T −,f u r t h e rA B V D
PET+, BEACOPPescc
ABVD: doxorubicin, bleomycin, vinblastine, dacarbazine; BEACOPP: bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine,
prednisone; BMT: blood or marrow transplantation; EORTC: European Organization for Research and Treatment of Cancer; esc, escalated; GELA: Groupe
d’´ EtudedesLymphomesdel’Adulte;GHSG:GermanHodgkinStudyGroup;GITIL:GruppoItalianoTerapieInnovative NeiLinfomi;IIL:Intergruppo Italiano
Linfomi; NCRI: National Cancer Research Institute; RATHL: response-adapted therapy in Hodgkin lymphoma; RT: radiation therapy; SWOG: Southwest
Oncology Group.
aRT restricted to residual ≥2.5cm, PET+ sites on end-of-chemotherapyimaging.
bIf PET− after 4 cyclesof BEACOPPesc ± rituximab, changed to standard BEACOPP ± rituximab.
cStandard BEACOPP if human immunodeﬁciency virus positive.
5.2. Risk-Adapted Approaches in Advanced HL. In current
risk-adapted trials for advanced HL based on metabolic
imaging, the main questions are twofold: (a) whether treat-
ment intensiﬁcation improves outcome in interim PET
positive patients and (b) whether toxicity can be minimized
in interim PET negative patients (Table 2).
Improved prognostication could identify which HL
patients can beneﬁt the most from intensiﬁed butmore toxic
chemotherapy. Escalated BEACOPP is an eﬀective ﬁrst-line
regimen that, compared to COPP-ABVD (cyclophospham-
ide-vincristine-procarbazine-prednisone-ABVD) and stan-
dard BEACOPP, confers superior FFP and overall survival
r a t e sa t5y e a r s[ 63] and beyond [64]i na d v a n c e dH L .
However, it is also more toxic, including increased risk of
acute hematologic toxicity, infertility, and myelodysplasia
or leukemia [63]. Although escalated BEACOPP appears
to be superior to ABVD in disease control [65, 66], its
greater toxicity,combined with the ability to salvage relapsed
patients [65], has hindered its widespread acceptance as the
new standard of care.
IntheinterimPETpositivepatients,escalationoftherapy
from ABVD to a BEACOPP regimen is among the approach-
es under investigation [51, 53, 54]. In the ﬁrst published
study of risk-adapted therapy in HL using interim metabolic
imaging [13], 108 patients had therapy tailored using 67Ga
scintigraphy or PET performed after 2 cycles of standard or
escalated BEACOPP. Pretreatment risk factors determined
the initial regimen, with that regimen continued, escalated,
or de-escalated according to the interim functional imaging
result. Treatment failure occurred in 2% of patients with
negative interim PET and 27% of patients with positive
interim PET. Notably, 79% of the patients initially deemed
high-risk had therapy reduced to standard BEACOPP, and
overall survival rates were similar in the intermediate-
risk and high-risk groups [13]. Although this approach
has not been studied in a randomized fashion, the results
demonstrate that, even among patients deemed to be high-
risk by pretreatment indices, a minority require intensiﬁed
upfront therapy.
The several ongoing trials involving change from ABVD
to BEACOPP in advanced HL [51, 53, 54] will not directly
prove the utility of this approach as compared with con-
tinued ABVD. They will, however, provide important data
that, together with the H10 trial in limited stage HL (which
has both standard and experimental arms) [49]w i l lh e l p
answerthisquestion.Twotrials[50,53]willalsointerestingly6 Advances in Hematology
address the contribution of rituximab, a drug that has
activity in classical HL despite the usual absence of CD20 on
Reed-Sternberg cells [67, 68].
In the interim PET negative patients, investigational
approaches include reduction in the number of chemother-
apy cycles, omission of bleomycin (given its risk of pul-
monary toxicity), and omission of consolidative RT
(Table 2). With respect to the latter, the role of RT in
advanced stage HL is undeﬁned [69–72] and practices vary.
For example, in a randomized study of advanced stage
HL patients achieving an anatomic complete remission
to chemotherapy, there was no diﬀerence in 5-year sur-
vival, and there was a tendency toward inferior survival,
with RT [69]. In a meta-analysis of chemotherapy ver-
sus chemoradiation for advanced HL, RT was associated
with a signiﬁcantly inferior overall survival [70]. On the
other hand, a retrospective study in advanced HL found
a progression-free and overall survival advantage to RT,
despite more of the radiated patients having initial bulky
disease and partial remissions after chemotherapy [72].
BEACOPP, as originally developed, included focal RT to
sites of initial bulky disease or residual tumor [63]. More
recently, end-of-chemotherapy PET scan has been utilized
to limit RT to residually FDG avid masses after BEACOPP,
with encouraging preliminary results [15]. The HD18 trial
omits RT altogether in patientsa c h i e v i n gan e g a t i v ec y c l e
2 PET after escalated BEACOPP [50]. Other multicenter
trials for advanced HL (HD0801, HD0607) are investi-
gating RT omission in a randomized fashion in patients
with negative interim and end-of-chemotherapy PET scans
[52, 53].
6.PrognosticationthroughMetabolic
Imaging inRelapsed orRefractoryHL
Inpatients with HL, high-dose therapywith BMTis reserved
for the relapsed or refractory setting. Although an overall
survival advantage has yet to be demonstrated, high-dose
therapy with BMT prolongs event-free survival in patients
with relapsed HL and is potentially curative [73]. In relapsed
HL, autologous BMT is associated with a 5-year event-free
survivalofapproximately40%–50%,althoughlatetreatment
failures occur [74–76].
In both HL and NHL, it is widely recognized that one
of the leading determinants of outcome is the sensitivity
of the tumor to salvage chemotherapy administered as a
bridge to transplantation [74, 75, 77, 78]. Failure rates after
BMT are excessive in the context of resistant relapse [79].
CT has been the standard imaging modality for determi-
nation of response, and therefore potential chemosensi-
tivity and candidacy for transplantation, following salvage
chemotherapy. However, a growing literature suggests that
the presence ofresidual metabolic activity in the tumorprior
to transplantation is prognostically signiﬁcant and may be
superior to anatomic response assessment (Table 3)[ 45, 80–
84]. As reviewed previously [85], many of the studies of
interim, pretransplantation PET are heterogeneous in terms
of disease (combination of HL and NHL, primary refrac-
tory and relapsed cases), design (retrospective, prospec-
tive), and metabolic response criteria. Table 3 summarizes
selectedstudiesofmetabolicimagingperformedaftersalvage
chemotherapy, prior to high-dose therapy with autologous
BMT, in patients with relapsed or refractory HL [45, 81–
84]. The literature suggests that residual PET positive disease
prior to transplantation portends worse outcomes. This is
i l l u s t r a t e db yas t u d yb yM o s k o w i t ze ta l .[ 45], whose group
previously found that initial remission under one year, active
B symptoms, and extranodal disease were associated with
inferior outcomes in relapsed HL. In patients who were
chemoresponsive by CT criteria, there was no apparent
diﬀerence in outcome according to the number of these risk
factors provided that pretransplantation metabolic imaging
(via gallium scintigraphy or PET) was negative [45].
How might this prognostic information be utilized?
Further, prospective studies as to whether metabolic imaging
complements pretreatment clinical risk scores in HL would
be of interest [82]. Although PET may more accurately
identify poor-risk patients who are less likely to beneﬁt from
autologous BMT, outcomes are far from all-or-none. The
available literature does not support withholding transplan-
tation to an otherwise appropriate, “responding” patient
with HL on the basis of a positive interim PET. Whether,
however, selected patients stand to beneﬁt more from an
alternative salvage approach such as allogeneic transplan-
tation is a question that warrants further study. Rather
than relying solely on the chemotherapy or chemoradiation
in the preparative regimen, an allogeneic transplant oﬀers
the possibility of an immunologic attack against the tumor
via a graft-versus-lymphoma eﬀect [74]. This is especially
attractive in a lymphoma that responds suboptimally to
chemotherapy.
7.General Considerationsin Analyzing
theMidtreatmentPET
For the prognostication of HL in clinical trials, performing
an interim PET after two or three cycles of chemotherapy
seems optimal (Tables 1 and 3). To avoid the transient ﬂuc-
tuations in FDG uptake that may occur after chemotherapy
[86] and to permit the chemotherapy to take eﬀect, an
interimPET should beperformed asclosetothe nextcycleas
possible. This consideration is balanced against the logistics
of obtaining the centralized read promptly and keeping
treatment on schedule, which is feasible [87].
In addition to causes of false positive and false negative
results, a number of issues surround the interpretation of
FDG PET scans that are highly relevant for prognostication.
These includethecriteriautilizedformetabolicresponse and
the reproducibly of the read, as brieﬂy reviewed next.
7.1. Deﬁnition of Metabolic Response. A baseline PET is
advisable to facilitate the evaluation of subsequent scans.
Interim or posttherapy PET is most widely interpreted
using visual (qualitative) criteria. Yet, FDG uptake lies onAdvances in Hematology 7
Table 3: Selected studies of pretransplantation PET in relapsed/refractory Hodgkin’s lymphoma.
Study Prospective Type of
FI No. No. FI+ (%) PPV NPV EFS, FI+ EFS, FI– Median follow-up
Spaepen et al.
2003 [81] no PET 19 9 (47%) 78% 90% — — —
Schot et al.
2007 [82] yes PET 23
5 (22%)
NMR, 10
(43%) PMR
60% if
NMR,
70% if
PMR
75% if
CMR, 30%
if PMR
40% (2 y)
if NMR,
37% if
PMR
73% (2 y)
if CMR —
Jabbour et al.
2007 [83] no
67Ga or
PET 211 57 (27%) 74% 68% 23% (3 y) 69% (3 y) 34 mo for
nonrelapsed pts
PET 68 25 (37%) 72% 77% — — —
Castagna et al.
2009 [84] no
PET,
after 2
cycles
24 10 (42%) 90% 93% 10% (2 y) 93% (2 y) 24 mo
PET,
after 4
cycles
24 6 (25%) — — 0% (2 y) 78% (2 y) 24 mo
Moskowitz et al.
2010 [45] yes
67Ga or
PET 105 41 (39%) — — 33% (4 y) 77% (4 y) 7 y in surviving pts
CMR: complete metabolic remission; EFS: event-free survival; FI: functional imaging; Ga: Gallium; NMR: no metabolic remission; NPV: negative predictive
value; PMR: partial metabolic remission (residual intensityabove background level); PPV: positive predictive value; pts, patients.
a continuum. A challenge in metabolic response assess-
ment is the dichotomization of this continuous variable as
either “positive” or “negative” for the purposes of response
assessment, prognostication, and therapy. There has been
variation among studies (including the ongoing studies of
risk-adapted therapy) in what constitutes a “positive” or
a “negative” result and the reference background against
which tumor FDG uptake is compared (surrounding tissue,
mediastinal blood pool, mediastinal blood pool plus normal
liver). These criteria have not been validated. Particularly
diﬃcult are cases of low-level tumoral FDG uptake, just
above background, that are deemed unlikely to represent
malignancy but may [29]. The prognostic signiﬁcance of
such “minimal residual uptake” may vary depending on the
pretest probability of treatment failure [88].
A standardized set of criteria for interim PET analysis
is needed [89]. Without this, the results of the risk-adapted
studies may be diﬃcult to generalize. The International
Harmonization Project criteria utilized for posttreatment
response designation were not developed for, nor are recom-
mended for, midtreatment response assessment [9]. These
criteria may be prone to high rates of interim PET positivity;
any activity above local background in a less than 2cm mass
including in normal size lymph nodes is considered positive
(to account for eﬀects of partial volume averaging), as is any
activity above mediastinal blood pool in a larger mass [9].
A prospective trial is evaluating a cutoﬀ of 1.5 times blood
poolactivityfordiﬀerentiatingbetweenpositiveandnegative
results in NHL [90].
In addition to whether a PET is “positive,” the intensity
of residual FDG uptake may have prognostic signiﬁcance
[44]. A 5-point scale (the Deauville criteria [91], based on
the “London” criteria [88]) that captures gradations in FDG
uptake has been proposed for interim response assessment,
with scores of 4 or 5 considered “positive”:
(1) no uptake above background,
(2) uptake ≤ mediastinum,
(3) uptake > mediastinum but ≤ normal liver,
(4) uptake moderately > liver,
(5) uptake markedly > l i v e ra n d / o rn e wd i s e a s e .
International validation studies of the 5-point scale are
in progress. As with any criteria that categorize a continuous
variable, discriminating subtle diﬀerences between FDG
uptake in tumor as compared to mediastinum or liver may
be challenging. Diﬀerences in outcome in patients with a
score of 2 versus 3 will be of particular interest in studies of
interimPET.Forthepurposesofprognosticationandclinical
trial planning, what should deﬁne a positive or a negative
i n t e r i mP E Tr e s u l t ?T h i si sn o ty e tk n o w n ,b u tm a yd e p e n d
upon the risks of the planned intervention. For instance,
if intensiﬁcation (with risks of overtreatment and greater
toxicity) is considered on the basis of a positive interim
PET, a conservative approach to PET interpretation may be
prudent, with borderline cases scored as negative [44]. If de-
escalation is considered on the basis of a negative PET, it
may be prudent to score such cases as positive so as to avoid
undertreatment.
Semiquantitative assessments using standardized uptake
values (SUVs) may complement visual criteria, at least in
NHL [92, 93] ,b u th a v en o tb e e ns h o w nt ob es u p e r i o rt o
qualitative assessments. This clearly warrants further study,8 Advances in Hematology
however, as PET is inherently a quantitative imaging method
[94]. Criteria for response assessment in solid tumors based
on SUVs have been proposed [94].
7.2. Reproducibility of the PET Read. Discordance in the PET
interpretation is a recognized concern, even if performed
by expert nuclear medicine physicians. The interobserver
variability is exempliﬁed by an expert panel’s analysis of
interim PET scans in diﬀuse large B-cell lymphoma, wherein
there was only moderate agreement using predeﬁned visual
criteria including the London criteria [95]. Additionally, no
consensus could be reached in 9 of 12 discordant cases,
with sites of para-aortic disease, spleen, and bone posing
particular diﬃculty [95]. In a multicenter trial for stage
II–IV HL, concordance in reads among four centers has
been preliminarily studied using the London criteria [88].
Very good agreement (kappa statistic, 0.85) was found for
a conservative reading (“positive” deﬁned as a score of 4
or 5), and good agreement (kappa statistic, 0.79) for a
sensitive reading (“positive” deﬁned as a score of 3, 4, or
5) [88]. Other investigations of the reproducibility of PET
readsinmulticentertrialsare inprogress. Giventhepotential
for greater interobserver reproducibility of semiquantitative
measures [94, 96], further eﬀorts to develop and validate
semiquantitativecriteria are encouraged.The reproducibility
of the PET interpretation is key if treatment decisions are
rendered on the basis of the PET result. Coupled with the
need for standardized, reproducible reporting is the clear
need for quality-control measures and consistent scanning
techniques in multicenter trials [97].
8.Conclusions
In HL, as in NHL, early prognostication through interim
PETclearlyhasthepotentialtoguideoptimaltreatment. The
metabolic imaging result has changed the deﬁnitions of dis-
easeresponse andchemosensitivity.However,many method-
ological and management questions remain. Although it is
tempting to incorporate interim PET scanning into routine
practice [98], such imaging is best performed on a clinical
trial. How to manage the result isnot yet established, butwill
be clariﬁed through ongoing and planned clinical trials.
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